Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKMerryn Voysey, Angela M. Minassian, Sue Ann Costa Clemens et al.|The Lancet|2020Cited by 5k
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trialsMerryn Voysey, Angela M. Minassian, Sue Ann Costa Clemens et al.|The Lancet|2021Cited by 1.2k
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialAlasdair Munro, Nick Andrews, Shuo Feng et al.|The Lancet Infectious Diseases|2022Cited by 180
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trialBenjamin A. Fisher, K Turner, Nicholas Morley et al.|UCL Discovery (University College London)|2022Cited by 58
Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) VaccineMerryn Voysey, Alastair McGregor, Sue Ann Costa Clemens et al.|SSRN Electronic Journal|2021Cited by 31